06/26/2026
A new era of flu vaccination may be getting closer.
FDA reviewers have found no major safety or efficacy concerns with Moderna’s experimental mRNA flu vaccine, known as mRNA-1010 / mFlusiva. If ultimately approved, it could become the first mRNA-based seasonal influenza vaccine authorized in the United States.
The vaccine is designed for adults 50 and older and uses mRNA technology to train the immune system against influenza strains. Unlike traditional flu shots, which can take longer to manufacture and update, mRNA vaccines may be adjusted more rapidly as flu viruses evolve — a major advantage against a disease that changes every year.
On June 18, 2026, FDA advisers unanimously voted that the vaccine’s benefits outweigh its risks, marking a major step forward. However, the vaccine still awaits the FDA’s final approval decision.
Source: Fiore, K. (2026, June). FDA reviewers raise no major concerns about Moderna’s mRNA flu vaccine ahead of advisory meeting. MedPage Today. Additional reporting: Reuters / FDA advisory materials.